Genetic stratification of neuroblastoma for treatment tailoring

Future Oncology

Volumn 7, Issue 9, 2011, Pages 1087-1099

  Jeison, Marta ^a   Yaniv, Isaac ^a,b   Ash, Shifra ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

aCGH; epigenetic profile; genetic subtyping; neuroblastoma; PAM classifier; risk stratification; SNP

Indexed keywords

BIOLOGICAL MARKER; BLU PROTEIN; CASPASE 8; DCR2 PROTEIN; DCR4 PROTEIN; DNA; HIN 1 PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE A; ONCOPROTEIN; OSTEONECTIN; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SURVIVIN; THROMBOSPONDIN 1; TIG 1 PROTEIN; TMS 1 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

AGE; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; CPG ISLAND; EPIGENETICS; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GENETICS; GENOME; GENOTYPE; HISTOPATHOLOGY; HUMAN; NEUROBLASTOMA; ONCOGENE; PHENOTYPE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE; TUMOR GROWTH;

COMPARATIVE GENOMIC HYBRIDIZATION; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; PROGNOSIS; TELOMERE;

EID: 80052980232     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.87     Document Type: Review

References (76)

1. Maris JM. Recent advances in neuroblastoma. N Engl. J. Med. 362, 2202-2211 (2010).
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3, 203-216 (2003). (Pubitemid 37328872)
3. Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N. Engl. J. Med. 341, 1165-1173 (1999). (Pubitemid 29480654)
4. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11, 1466-1477 (1993). (Pubitemid 23228250)
5. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 369, 2106-2120 (2007). (Pubitemid 46935947)
6. London WB, Castleberry RP, Matthay KK et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J. Clin. Oncol. 23, 6459-6465 (2005). (Pubitemid 46190236)
7. George RE, London WB, Cohn SL et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 23, 6466-6473 (2005). (Pubitemid 46190237)
8. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med. Pediatr. Oncol. 6, 508-515 (2003). (Pubitemid 37386067)
9. Castel V, Villamón E, Cañete A et al. Neuroblastoma in adolescents: genetic and clinical characterisation. Clin. Transl. Oncol. 12(1), 49-54 (2010).
10. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi V V, Roald B. The International Neuroblastoma Pathology Classification (Shimada) System. Cancer 86, 364-372 (1999). (Pubitemid 29327594)
11. Peuchmaur M, d'Amore ESG, Joshi VV et al. Revision of International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98, 2274-2281 (2003). (Pubitemid 37392433)
12. Sano H, Bonadio J, Gerbing RB et al. International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. Eur. J. Cancer 42, 1113-1119 (2006).
13. Look AT, Hayes FA, Nitschke R et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N. Engl. J. Med. 311, 231-235 (1984). (Pubitemid 14087665)
14. Look AT, Hayes FA, Shuster JJ et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 9, 581-591 (1991).
15. Ladenstein R, Ambros IM, Potschger U et al. Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med. Pediatr. Oncol. 36, 83-92 (2001).
16. Ambros PF, Ambros IM, Brodeur GM et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br. J. Cancer 100, 1471-1482 (2009). □□ Emphasizes the necessity to identify significant genetic markers for neuroblastoma by reliable methods, and provide consensus for methodology nomenclature and future directions for neuroblastoma treatment management.
17. Cohn SL, Pearson AD, London WB et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 27, 289-297 (2009). □□ Describes in details the new International Neuroblastoma Risk Group staging and classification system.
18. Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313, 1111-1116 (1985). (Pubitemid 16216827)
19. Schneiderman J, London WB, Brodeur GM et al. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J. Clin. Oncol. 26, 913-918 (2008). (Pubitemid 351398084)
20. Bagatell R, Beck-Popovic M, London W et al.; International Neuroblastoma Risk Group: Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J. Clin. Oncol. 27, 365-370 (2009).
21. Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J. Clin. Oncol. 26(6), 913-918 (2008). (Pubitemid 351398084)
22. Jeison M, Ash S, Halevy-Berko G et al. 2p24 gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma. Am. J. Pathol. 176(6), 2616-2625 (2010).
23. Theissen J, Boensch M, Spitz R et al. Heterogeneity of the MYCN oncogene in neuroblastoma. Clin. Cancer Res. 15, 2085-2090 (2009).
24. Maris JM, Weiss MJ, Guo C et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J. Clin. Oncol. 18, 1888-1899 (2000). (Pubitemid 30261926)
25. Caron H, van Sluis P, de Kraker J et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N. Engl. J. Med. 334, 225-230 (1996). (Pubitemid 26030673)
26. Fujita T, Igarashi J, Okawa ER et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl Cancer Inst. 100, 940-949 (2008). (Pubitemid 351957513)
27. Henrich KO, Bauer T, Schulte J et al. CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res. 71, 3142-3151 (2011).
28. Caren H, Fransson S, Ejeska K, Kogner P, Martinsson T. Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br. J. Cancer 97, 1416-1424 (2007). (Pubitemid 350114785)
29. Plantaz D, Vandesompele J, Van Roy N et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int. J. Cancer 91, 680-686 (2001). (Pubitemid 32115264)
30. Attiyeh EF, London WB, Mosse YP et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353, 2243-2253 (2005). (Pubitemid 41697287)
31. Fischer M, Bauer T, Oberthür A et al. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 29, 865-875 (2010).
32. Carén H, Kryh H, Nethander M et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc. Natl Acad. Sci. USA 107, 4323-4328 (2010).
33. Michels E, Hoebeeck J, De Preter K et al. CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer 8, 173 (2008).
34. Bown N, Cotterill S, Lastowska M et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med. 340, 1954-1961 (1999). (Pubitemid 29288271)
35. Stark B, Jeison M, Glaser-Gabay L et al. der (11) t (11;17): a distinct cytogenetic pathway of advanced stage neuroblastoma (NBL) - detected by spectral karyotyping (SKY). Cancer Lett. 197, 75-79 (2003). (Pubitemid 36859993)
36. Normand C, Michon J, Janoueix-Lerosey I, Delattre O, Schleiermacher G. Genetic alterations in neuroblastoma and their usefulness for clinical management. Bull. Cancer 98(5), 477-488 (2011).
37. Mosse YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
38. George RE, Sanda T, Hanna M et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
39. Janoueix-Lerosey I, Lequin D, Brugieres L et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
40. Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
41. Mosse YP et al. Germline PHOX2B mutatio in hereditary neuroblastoma. Am. J. Hum. Genet. 75, 727-730 (2004). (Pubitemid 39244788)
42. Monclair T, Brodeur GM, Ambros PF et al.; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J. Clin. Oncol. 27, 298-303 (2009).
43. Mueller S, Matthay KK. Neuroblastoma: biology and staging. Curr. Oncol. Rep. 11(6), 431-438 (2009).
44. Brinkschmidt C, Potemba C, Christiansen H et al. Comparative genomic hybridization an telomerase activity analysis identify two biologically different groups of neuroblastoma. Br. J. Cancer 77, 2223-2229 (1998). (Pubitemid 28263945)
45. Vandesompele J, Van Roy N, Van Gele M et al. Genetic heterogeneity of neuroblastoma studied by comparative geneomic hybridization. Genes Chromosomes Cancer 23 151-152 (1998).
46. Lastowska M, Cullinanc C, Variend S et al.; for the United Kingdom Children Cancer Study Group and the United Kingdom Cancer Cytogenetic Group. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J. Clin. Oncol. 19, 3080-3090 (2001). □ For the first time, combines ploidy, genetic markers, morphology and clinical features; redefines neuroblastoma genetic types and outlines a model of neuroblastoma development. (Pubitemid 32565447)
47. Schleiermacher G, Michon J, Huon I et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br. J. Cancer 97, 238-246 (2007). (Pubitemid 47057465)
48. Michels E, Vandesompele J, De Preter K et al. Array CGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 46, 1098-1108 (2007). (Pubitemid 47614544)
49. Tomioka N, Oba S, Ohira M et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 27, 441-449 (2008).
50. Janoueix-Lerosey I, Schleiermacher G, Michels E et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 27, 1026-1033 (2009). □□ Analyzed a cohort of neuroblastoma by array comparative genomic hybridization and suggests that any segmental alteration is associated with an increased risk or relapse, being the overall genomic pattern more indicative of disease behavior than individual genetic markers.
51. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A et al. Accumulation of segmental alterations determines progression in neuroblastoma, J. Clin. Oncol. 28, 3122-3130 (2010).
52. Mossé YP, Greshock J, Weber BL, Maris JM. Measurement and relevance of neuroblastoma DNA copy number changes in the postgenome era. Cancer Lett. 228, 83-90 (2005). (Pubitemid 41188428)
53. Spitz R, Oberthuer A, Zapatka M et al. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastoma reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 45, 1130-1142 (2006). (Pubitemid 44763441)
54. George R, Attiyeh E, Li S et al. Genome-wide analysis of neuroblastoma using high-density single nucleotide polymorphism arrays. PloS One 2, E255-E277 (2007).
55. Carr J, Bown NP, Case MC et al. High resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genet. Cytogenet. 172, 127-138 (2007). (Pubitemid 46043573)
56. Carén H, Erichsen J, Olsson L et al. High-resolution array copy number analyses for detection of deletion, gain, amplifcation and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 9, 353-365 (2008).
57. Caren H, Erichsen J, Olsson L et al. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 9, 353-365 (2008).
58. Vandesompele J, Baudis M, De Preter K et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J. Clin. Oncol. 23, 2280-2299 (2005). □ Meta-analysis report on CGH data using a unique data-mining strategy suitable for multivariate survival analyses of all genetic imbalances detected by CGH. (Pubitemid 46218721)
59. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences bymultiplex ligation-dependent probe amplification. Nucleic Acids Res. 30, E57 (2002).
60. Ambros IM, Brunner B, Aigner G et al. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin. Cancer Res. 17, 792-804 (2011). □ Interlaboratory study to establish and validate the PCR-based multiplex ligation-dependent probe amplification technique for neuroblastoma that is cost effective, reliable and reproducible.
61. Villamón E, Piqueras M, Mackintosh C et al. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchow Arch. 453, 47-55 (2008).
62. Schramm A, Schulte JH, Klein-Hitpass L et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24, 7902-7912 (2005). (Pubitemid 41715196)
63. Vermeulen J, De Preter K, Naranjo A et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet 10, 663-671 (2009).
64. Oberthuer A, Hero B, Berthold F et al. Prognostic impact of gene expression-based classification for neuroblastoma. J. Clin. Oncol. 28, 3506-3515 (2010).
65. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M. Molecular characterization and classification of neuroblastoma. Future Oncol. 5(5), 625-639 (2009). □ Valuable report reviewing updated molecular information obtained by genome-wide methods and altered signaling pathways in aggressive neuroblastoma.
66. Fischer M, Berthold F. The role of complex genomic alterations in neuroblastoma risk estimation. Genome Med. 2, 31-34 (2010).
67. Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett. 18, 253-258 (2007). (Pubitemid 46240612)
68. Yang Q, Zage P, Kagan D et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neurobalstoma. Clin. Cancer Res. 10, 8493-8500 (2004). (Pubitemid 40053415)
69. Yang Q, Kiernan CM, Tian Y et al. Methylation of CASP8, DCR2, and HIN-1 in neuoblastoma. Clin. Cancer Res. 13, 3191-3197 (2007).
70. Yang Q, Tian Y, Ostler K et al. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer 10, 286-295 (2010).
71. Hiyama E, Hiyama K, Yokoyama T, Ichikawa T, Matsuura Y. Length of telomeric repeats in neuroblastoma: correlation with prognosis and other biological characteristics. Jpn J. Cancer Res. 83, 159-164 (1992).
72. Ohali A, Avigad S, Ash S et al. Telomere length is a prognostic factor in neuroblastoma. Cancer 107, 1391-1399 (2006). (Pubitemid 44452790)
73. Lundberg G, Sehic D, Lansberg J et al. Alternative lengthening of telomeres - an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer 50, 250-262 (2011).
74. Volchenboum SL, Cohn SL. Are molecular neuroblastoma classifiers ready for prime time? Lancet Oncol. 10, 641-642 (2009).
75. Volchenboum SL, Cohn SL. Progress in defining and treating high-risk neuroblastoma: lessons from the bench and bedside. J. Clin. Oncol. 27, 1003-1004 (2009).
76. Van Roy N, De Preter K, Hoebeeck J et al. The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med. 1, 74 (2009).